🟢 Veru is trading 6% up in pre-market; catalyst remains unclear

Veru is trading 6.29% up at $2.79, with no new company-specific announcement identified for August 31, 2026 and the immediate catalyst unclear.

• Latest major catalyst: Veru’s August 10 fiscal third-quarter update, reporting full enrollment in the 239-patient PLATEAU trial and a planned Q1 2027 interim analysis.
• The broader market is slightly lower pre-market, so the gain does not appear tied to overall index direction.
• No fresh filing, earnings release, FDA decision, or clearly reported analyst action was found overnight.